close
 |
Clear My Agenda & Abstract Book |
Print My Agenda |
Print My Abstract Book
Download My Agenda in PDF | Download My Agenda in iCal
Download My Agenda in PDF | Download My Agenda in iCal
HPV 2010 Programme
>> Poster Viewing - Basic Sciences
| Description | Room |
|
|||
|---|---|---|---|---|---|
| L |
P-100: Novel papillomavirus isolated from the mucosa of a spotted hyena (Crocuta crocuta) clusters within the lambdapapillomavirus genus.
|
|
Add to my agenda | ||
| L |
P-101: The first complete papillomavirus characterized from a marsupial host, the Bettongia penicillata papillomavirus type 1.
|
|
Add to my agenda | ||
| L |
P-102: novel equine papillomavirus clusters only roughly with other equine papillomaviruses
|
|
Add to my agenda | ||
| L |
P-103: snake papillomavirus does not cluster with other non mammalian-papillomaviruses
|
|
Add to my agenda | ||
| L |
P-104: Novel cetacean papillomaviruses exhibit both chimeric and non-recombinant genome organizations
|
|
Add to my agenda | ||
| L |
P-105: Novel monkey betapapillomavirus associated with hand and foot papillomas
|
|
Add to my agenda | ||
| L |
P-106: gamma secretase inhibitors function as potent hpv microbicides
|
|
Add to my agenda | ||
| L |
P-107: Carraguard, a vaginal microbicide, protects women against HPV infection
|
|
Add to my agenda | ||
| L |
P-108: Sulindac inhibits proliferation and induces apoptosis in cervical cancer cell lines
|
|
Add to my agenda | ||
| L |
P-109: The Susceptibility of HPV16 Native and Quasivirus Particles to Clinically Relevant Disinfectants
|
|
Add to my agenda | ||
| L |
P-110: In vitro selection of RNA aptamers to HPV-16 L1 VLPs
|
|
Add to my agenda | ||
| L |
P-111: Gene expression profiling in cidofovir-treated and cidofovir-resistant SiHa cells
|
|
Add to my agenda | ||
| L |
P-112: Human Papillomavirus 6/11-Specific T-cells Binding Class II Tetramer-E2/E6 Complexes elicit reduced IFN-?
|
|
Add to my agenda | ||
| L |
P-113: Analysis of cellular immunity parameters in women with HPV infections
|
|
Add to my agenda | ||
| L |
P-114: Reversal of HPV-Mediated Suppression of Langerhans Cell Function with the TLR3 Agonist PolyICR
|
|
Add to my agenda | ||
| L |
P-115: DETECTION OF HUMAN PAPILLOMAVIRUS TYPE 16 E7-SPECIFIC T CELLS BY ELISPOT ASSAY
|
|
Add to my agenda | ||
| L |
P-117: Cellular immune response to human papillomavirus 58 L1, E6 and E7 in Chinese women with transient infections and cervical neoplasia
|
|
Add to my agenda | ||
| L |
P-118: Cellular immune response to human papillomavirus 52 L1, E6 and E7 in Chinese women with different grades of cervical lesion
|
|
Add to my agenda | ||
| L |
P-119: Sequence variations of human papillomavirus type 58 E2, E4 and E5 genes across the world
|
|
Add to my agenda | ||
| L |
P-120: Correlation of mucosal type1 immune response to oncogenic human papillomavirus (HPV) in cervical T cells to fate of precursor lesions of cervical cancer.
|
|
Add to my agenda | ||
| L |
P-121: Cytokine levels in cervicovaginal secretions of women with High Squamous Intraepithelial Lesions (HSIL)
|
|
Add to my agenda | ||
| L |
P-122: Immunological aspects of HPV infection
|
|
Add to my agenda | ||
| L |
P-123: IFN-?, IL-12, IL-18 and HPV in cervical carcinogenesis
|
|
Add to my agenda | ||
| L |
P-125: Sequence variation of Human Papillomavirus Type 58 E7 across the world
|
|
Add to my agenda | ||
| L |
P-126: HPV Genotypes in Luanda, Angola
|
|
Add to my agenda | ||
| L |
P-127: Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions
|
|
Add to my agenda | ||
| L |
P-128: Characterisation of a Novel Cutaneous Human Alpha-papillomavirus Genotype HPV-125
|
|
Add to my agenda | ||
| L |
P-129: Characterisation of a Novel Human Papillomavirus Genotype HPV-151 from species 2 of Beta-papillomaviruses
|
|
Add to my agenda | ||
| L |
P-130: Characterisation of a Novel Human Beta-papillomavirus Genotype HPV-150 related to HPV-96
|
|
Add to my agenda | ||
| L |
P-131: HPV complete genome sequence imputation from partial sequence information
|
|
Add to my agenda | ||
| L |
P-132: E6 and E7/HPV58 variants in women with normal cytology from the Colombian cohort.
|
|
Add to my agenda | ||
| L |
P-133: HPV-16 intratype variation in women attending gynecological outpatient department during 2009 in Spain
|
|
Add to my agenda | ||
| L |
P-134: HPV in women from Ouro Preto,Brazil with normal cervical cytology.
|
|
Add to my agenda | ||
| L |
P-135: The clinical importance of understanding the evolution of papillomaviruses
|
|
Add to my agenda | ||
| L |
P-136: spectral phenotype of oncogenic HPV-infected exfoliative cervical cytology
|
|
Add to my agenda | ||
| L |
P-137: A competitive serology assay shows protection against HPV infection by natural titers in the Guanacaste Natural History Study
|
|
Add to my agenda | ||
| L |
P-138: Multiple HPV serum antibodies are more evident in women than men
|
|
Add to my agenda | ||
| L |
P-139: Seroprevalence of seven high risk HPV types in the Dutch population.
|
|
Add to my agenda | ||
| L |
P-140: Calibration of an HPV 6/11/16/18 Serology Standard to an Internal Standard and WHO 05/134 for HPV 16
|
|
Add to my agenda | ||
| L |
P-141: The relationship between memory B cells and systemic antibodies after HPV VLP vaccination
|
|
Add to my agenda | ||
| L |
P-142: Development of a GuHCl-modified ELISA for measuring the avidity of anti-HPV VLP antibodies
|
|
Add to my agenda | ||
| L |
P-143: Low avidity of HPV 16 antibodies is associated with increased susceptibility to low- but not high-risk HPV infections
|
|
Add to my agenda | ||
| L |
P-144: Detection of anti-HPV serum antibodies 3 to 12 years after detection of HPV DNA in genital samples from young women
|
|
Add to my agenda | ||
| L |
P-145: Mucosal immune responses of the anus and cervix to HPV in the same women.
|
|
Add to my agenda | ||
| L |
P-146: Transcriptional regulation of E-cadherin by HPV16 E6
|
|
Add to my agenda | ||
| L |
P-147: Human papillomavirus associated loss of E-cadherin expression is conserved across all but the β genera.
|
|
Add to my agenda | ||
| L |
P-148: Correlation of local inflammatory cytokines and HPV clearance induced by cryosurgery
|
|
Add to my agenda | ||
| L |
P-149: Alteration of Plasma TH2-chemokines in Patients with Recurrent Respiratory Papillomatosis (RRP) treated with Celecoxib
|
|
Add to my agenda | ||
| L |
P-150: Select Micro-RNA's (miRNA's) are Upregulated in HPV-6 and -11 Induced Recurrent Respiratory Papillomatosis (RRP).
|
|
Add to my agenda | ||
| L |
P-151: The altered HLA class I and HLA-G expression is associated with IL-10 expression in patients with cervical cancer.
|
|
Add to my agenda | ||
| L |
P-152: comparison of normalization methods for measuring immune markers in cervical secretion specimens
|
|
Add to my agenda | ||
| L |
P-153: Simple and convenient methods for purifying pseudovirus of human papillomavirus type 58
|
|
Add to my agenda | ||
| L |
P-154: Identification of suitable endogenous control molecules for microRNA expression analysis in human cervical tissues
|
|
Add to my agenda | ||
| L |
P-155: The feasibility of PapilloCheck HPV testing on stored SurePath vials.
|
|
Add to my agenda | ||
| L |
P-156: DNA extraction from residual cell-pellet and SurePath vial for PapilloCheck DNA-testing.
|
|
Add to my agenda | ||
| L |
P-157: Comparing PapilloCheck HPV-DNA testing and immunocytochemistry on SurePath specimens.
|
|
Add to my agenda | ||
| L |
P-158: Validation of L-shape endo/esocervical flocked swab and CyMol transport medium with NucliSENS EasyQ® HPV v1.1 assay
|
|
Add to my agenda | ||
| L |
P-159: Identification of suitable endogenous control genes for microRNA gene expression analysis in human cervical tissues
|
|
Add to my agenda | ||
| L |
P-160: Human papillomavirus genotype detection from archival Papanicolaou-stained cervical smears
|
|
Add to my agenda | ||
| L |
P-161: Confirmation of HC2 positive/cytology normal women by Papillocheck and Roche Line Blot assay
|
|
Add to my agenda | ||
| L |
P-162: The First WHO HPV LabNet International Proficiency Study of HPV Serology
|
|
Add to my agenda | ||
| L |
P-164: External quality assessment for molecular detection of human papillomaviruses
|
|
Add to my agenda | ||
| L |
P-165: Mapping virus integration sites in HPV16+ oral cancers by real time PCR.
|
|
Add to my agenda | ||
| L |
P-166: Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR.
|
|
Add to my agenda | ||
| L |
P-167: APTIMA HPV assay - Clinical Performance
|
|
Add to my agenda | ||
| L |
P-168: Clinical performance of Abbott RealTime High Risk HPV, APTIMA HPV and Papillocheck for detection of >CIN2+ lesions
|
|
Add to my agenda | ||
| L |
P-169: Novel real time genotyping assay for HPV 16 E6-350G Variant Detection
|
|
Add to my agenda | ||
| L |
P-170: Lack of type-specific concordance of Roche Linear Array® and Innogenetics InnoLiPa® performed on different DNA extracts
|
|
Add to my agenda | ||
| L |
P-171: Universal HPV genotyping of GP5+/6+-, Amplicor- and PGMY-amplimers by digene RH and LQ Tests
|
|
Add to my agenda | ||
| L |
P-172: Wart swabs are accurately reflecting the HPV type present inside the wart
|
|
Add to my agenda | ||
| L |
P-173: Analytical validation of the digene HPV Genotyping RH and LQ Tests
|
|
Add to my agenda | ||
| L |
P-174: Evaluation of Test Performance Characteristics and Operational Parameters of 5 HPV genotyping assays
|
|
Add to my agenda | ||
| L |
P-175: Reproducibility of early morning oral rinse self sampling for detection of oral HPV
|
|
Add to my agenda | ||
| L |
P-176: Evaluation of dry and wet transported cervical exfoliated samples for detection of human papillomavirus infection
|
|
Add to my agenda | ||
| L |
P-177: Enrichment of HPV-integrated gDNA from FFPE tissue for next-generation sequencing
|
|
Add to my agenda | ||
| L |
P-178: Evaluation of methods determining HPV prevalence in Condylomata acuminata
|
|
Add to my agenda | ||
| L |
P-179: Prevalence of human papilloma virus types and viral load - Pap test correlation in Romania
|
|
Add to my agenda | ||
| L |
P-180: MYCOBATERIUM ASSOCIATED IMMUNE RECONSTITUTION WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ( HAART) INITIATION
|
|
Add to my agenda | ||
| L |
P-181: colposcopy assessment does not predict the follow-up in women with hr-hpv infection and mild cytological abnormalities.
|
|
Add to my agenda | ||
| L |
P-182: Associations between race, oral sex, marijuana use and prevalent oral HPV infection in the Ohio S3 Study
|
|
Add to my agenda | ||
| L |
P-183: Updated data from the pregnancy registry for Gardasil® (human papillomavirus types 6/11/16/18 vaccine)
|
|
Add to my agenda | ||
| L |
P-184: Defective Natural Killer Cell (NK) Function In Patients with Recurrent Respiratory Papillomatosis (RRP).
|
|
Add to my agenda | ||
| L |
P-185: HPV: Immunization, screening and sexual behaviours
|
|
Add to my agenda | ||
| L |
P-186: Reactogenicity of the bivalent human papillomavirus vaccine
|
|
Add to my agenda | ||
| L |
P-187: Future directions for screening: modelling results from the ARTISTIC trial
|
|
Add to my agenda | ||
| L |
P-188: Cytology and Genotyping as Secondary Screens after Primary HPV Screening.
|
|
Add to my agenda | ||
| L |
P-189: Primary HPV screening with secondary VIA followed by cryotherapy
|
|
Add to my agenda | ||
| L |
P-190: Prospective randomized comparison of the POI/NIH and the Qiagen self-sampling brushes
|
|
Add to my agenda | ||
| L |
P-191: The Shenzhen Cervical Cancer Screening Trial II (SHENCCAST II)
|
|
Add to my agenda | ||
| L |
P-192: Effects of purification method in antigenicity and immunogenicity of human papillomavirus type 16 virus-like particle from Saccharomyces cerevisiae
|
|
Add to my agenda | ||
| L |
P-193: HPV L1 VLP-based vaccines formulated with AS04 induce cross-protection against infection and disease in the rabbit HPV quasivirion challenge model
|
|
Add to my agenda | ||
| L |
P-194: Immune responses of HPV16/18 bivalent DNA Vaccine; AcHERV-HP16/18L1
|
|
Add to my agenda | ||
| L |
P-195: Effects of adjuvants on subligual immunization of human papillomavirus 16L1 protein
|
|
Add to my agenda | ||
| L |
P-196: DNA vaccination via tattooing induces specific protective immunity in HLA-A2.1 transgenic rabbits
|
|
Add to my agenda | ||
| L |
P-197: Papillomavirus genome plasticity leads to protective vaccine study in HLA-A2.1 transgenic rabbits
|
|
Add to my agenda | ||
| L |
P-198: HPV16 E7 A2-restricted epitope-specific protective cellular immunity to early and late gene targets
|
|
Add to my agenda | ||
| L |
P-199: Protection against heterologous papillomavirus of oral administered HPV-16 L2 displayed on L. casei in Balb/C mice
|
|
Add to my agenda | ||
| L |
P-200: Impact of a Candidate Transmembrane Domain upon the Immunogenicity and Solubility of Multimeric L2 Vaccines
|
|
Add to my agenda | ||
| L |
P-201: Evaluation of an L2 multimer vaccine against diverse oncogenic HPV types
|
|
Add to my agenda | ||
| L |
P-202: Serum antibodies induced by HPV16 L1 VLP vaccination inhibit infection by blocking virus entry at two distinct steps in vivo
|
|
Add to my agenda | ||
| L |
P-203: Genital Immunization with HPV Pseudovirions Induces Persistent Effector Memory CD8+ T-Cell Responses in the Mouse Genital Tract
|
|
Add to my agenda | ||
| L |
P-204: Production and immunogenicity of a candidate vaccine to protect against multiple human papillomavirus types
|
|
Add to my agenda | ||
| L |
P-205: hpv-specific antibody titers necessary to prevent in vivo genital hpv-pseudovirion infection in mice
|
|
Add to my agenda | ||
| L |
P-206: Three point mutations within the HPV16 L1 FG loop are sufficient to define a new serotype escaping prophylactic HPV16 L1 vaccination
|
|
Add to my agenda | ||
| L |
P-207: Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA
|
|
Add to my agenda | ||
| L |
P-208: Anti-tumor effect of human papillomavirus type 16 E6- and E7-expressing Lactobacillus Casei
|
|
Add to my agenda | ||
| L |
P-209: Selective silencing of HPV16 E6 and E7 oncogenes expression by RNA in terference in cervical cancer cells
|
|
Add to my agenda | ||
| L |
P-210: Size-dependent immune properties of gold nanoparticles as a drug (vaccine) targeting carrier in nanomedicine- elicited by synthetic Foot-and-mouth disease virus peptide
|
|
Add to my agenda | ||
| L |
P-211: Disarmed plant toxins improve anti-HPV therapeutic vaccines.
|
|
Add to my agenda | ||
| L |
P-212: Combined Administration with DNA Encoding Vesicular Stomatitis Virus G Protein Enhances DNA Vaccine Potency
|
|
Add to my agenda | ||
| L |
P-213: Efficient Delivery of DNA Vaccines using Human Papillomavirus Pseudovirions
|
|
Add to my agenda | ||
| L |
P-214: Characterization of HPV-6b E7-specific immune responses generated by a DNA vaccine
|
|
Add to my agenda | ||
| L |
P-215: HPV pseudoviruses as gene delivery vectors for murine tumors and human ovarian tumor xenografts
|
|
Add to my agenda | ||
| L |
P-217: Role of the CXCL12-signalling axis in human papillomavirus life cycle and human keratinocyte transformation
|
|
Add to my agenda | ||
| L |
P-218: expressions of survivin and telomerase in cervix of women with Human Papillomavirus induced lesions
|
|
Add to my agenda | ||
| L |
P-219: Expression of Rho GTPases and their GEFs in cervical premalignant lesions.
|
|
Add to my agenda | ||
| L |
P-220: Non coding mitochondrial RNA as a new target for HPV16 oncoproteins
|
|
Add to my agenda | ||
| L |
P-221: MCM-2, E6 and Ki-67 expression in invasive cervical cancer
|
|
Add to my agenda | ||
| L |
P-222: CATECHOL-O-METHYLTRANSFERASE GENETIC POLYMORPHISM AND HOMOCYSTEIN LEVELS IN CERVIX CANCER
|
|
Add to my agenda | ||
| L |
P-223: Hypermethylation of HPV 16/18 E2 binding sites 1&2 is associated with better survival in cervical cancer
|
|
Add to my agenda | ||
| L |
P-224: Pro-cadherin 10: A novel methylation biomarker for triage of hrHPV positive women during cervical cancer screening
|
|
Add to my agenda | ||
| L |
P-225: Causative role of human papillomavirus in low-grade bladder carcinoma
|
|
Add to my agenda | ||
| L |
P-226: PTEN, hDlg AND p53 ABNORMAL EXPRESSION IN CERVICAL CARCINOGENESIS
|
|
Add to my agenda | ||
| L |
P-227: The role of chromosomal integration to induce the transforming type of HPV gene expression in cervical preneoplastic lesions
|
|
Add to my agenda | ||
| L |
P-228: Analyses of differentially-expressed and oxidatively modified proteins in dysplastic lesions and squamous cervical carcinomas
|
|
Add to my agenda | ||
| L |
P-229: HPV-16 E6 and E7 Alter NF-kB Activity in Human Cervical Cells
|
|
Add to my agenda | ||
| L |
P-230: Polymorphism and transcriptional activity of HPV16 Asian variant LCR in Thai women
|
|
Add to my agenda | ||
| L |
P-231: The -56C>T polymorphism and hypermethylation of the MGMT gene promoter in cervical cancer
|
|
Add to my agenda | ||
| L |
P-232: Methylation of the MGMT, FHIT, MLH1, MSH2 promoters in precancerous lesions and cervical cancer.
|
|
Add to my agenda | ||
| L |
P-233: DNMT3b expression and DNA methylation in precancerous lesions and HPV infection
|
|
Add to my agenda | ||
| L |
P-234: CpG methylation in the HPV16 3' L1/ 5'LCR region characterized from anal epithelia of HPV-HIV coinfected men
|
|
Add to my agenda | ||
| L |
P-235: Activation of the hTERT promoter by alpha HPV E6 proteins is associated with oncogenic risk
|
|
Add to my agenda | ||
| L |
P-236: Relationship between the expression of p16INK4a the age and genotypes determined by PCR SPF10-LiPA 25 in invasive cervical carcinomas
|
|
Add to my agenda | ||
| L |
P-237: HPV-16 E6 induces expression of RB and ROCK1 in keratinocytes
|
|
Add to my agenda | ||
| L |
P-238: HPV E6 does not require P53 degradation or PDZ domain interactions for cell immortalization
|
|
Add to my agenda | ||
| L |
P-239: Role of Pocket Proteins in HPV-associated Cancers
|
|
Add to my agenda | ||
| L |
P-240: The role of microRNA-196b in human cervical cancer
|
|
Add to my agenda | ||
| L |
P-241: HPV8 E6 differentially disrupts terminal keratinocyte differentiation and inhibits filaggrin maturation
|
|
Add to my agenda | ||
| L |
P-242: Profiling of cellular microRNA in epithelial cells expressing human papillomavirus 16 E5 oncogene
|
|
Add to my agenda | ||
| L |
P-243: Regulation of ERK signaling by the HPV E6/hScrib/PP1c signalling complex.
|
|
Add to my agenda | ||
| L |
P-244: Hras confers tumor-initiating properties through endogenous c-Myc on human cervical keratinocytes
|
|
Add to my agenda | ||
| L |
P-245: Analysis of HPV 16E6 protein in oncogenic transformation of human cervical keratinocytes.
|
|
Add to my agenda | ||
| L |
P-246: An in vitro multistep carcinogenesis model for both HPV positive and negative human oral squamous cell carcinoma
|
|
Add to my agenda | ||
| L |
P-247: endonuclease resistant dna: a new marker to identify and predict disease progression of human papilloma virus-infected lesions
|
|
Add to my agenda | ||
| L |
P-248: Evaluation of celecoxib in the HPV-11 infected xenograft-severe combined immunodeficiency (SCID) mouse
|
|
Add to my agenda | ||
| L |
P-249: HPV-induced proliferation - Gene expression profiling of the host effect
|
|
Add to my agenda | ||
| L |
P-250: Activation of two novel 5' splice site usage in RNA splicing of HPV16 E6E7 intron 1
|
|
Add to my agenda | ||
| L |
P-251: factors influencing hpv late gene expression
|
|
Add to my agenda | ||
| L |
P-252: Preliminary Evaluation of the APTIMA®HPV 16 18/45 Genotype Assay for the Detection of Human Papillomavirus Types 16, 18, and 45 in Liquid Pap Specimen
|
|
Add to my agenda | ||
| L |
P-253: Degradation of p53 and p27kip1 in C33A cell lines with stably expressing E6 HPV16 variant oncogene
|
|
Add to my agenda | ||
| L |
P-254: The HPV transcriptome in HPV16 positive cell lines
|
|
Add to my agenda | ||
| L |
P-255: Regulation of human papillomavirus type 16 expression in trophoblastic and cervical cells
|
|
Add to my agenda | ||
| L |
P-256: HPVE6/E7mRNA for cancer progression risk assessment in females/males asymptomatic populations
|
|
Add to my agenda | ||
| L |
P-257: Patterns of Cellular and HPV 16 DNA Methylation as Biomarkers for Cervical Neoplasia
|
|
Add to my agenda | ||
| L |
P-258: High throughput sequencing reveals a greater diversity of HPVs
|
|
Add to my agenda | ||
| L |
P-259: Identification of cis-acting sequences that suppress HPV-16 late 5'-splice site SD3632 in cervical cancer cells
|
|
Add to my agenda | ||
| L |
P-260: Integrative modelling of signalling pathways involved in cervical cancer progression: A multidisciplinary approach
|
|
Add to my agenda | ||
| L |
P-261: Gene expression profiling in cervical cancer: identification of candidate genes as markers for tumor invasion.
|
|
Add to my agenda | ||
| L |
P-262: HPV E6 AND E7 mRNA EXPRESSION ANALYSIS IN CERVICAL BIOPSY SPECIMENS
|
|
Add to my agenda | ||
| L |
P-263: Identification of gene regulatory abnormalities accompanying HPV 59 infection and integration
|
|
Add to my agenda | ||
| L |
P-264: High viral load and E7 expression among CaCx cases harboring intact E2: some novel insights on disease pathogenesis
|
|
Add to my agenda | ||
| L |
P-265: Identification of cellular transcription factors that regulate HPVs 18 and 16 early promoters
|
|
Add to my agenda | ||
| L |
P-266: lasermicrodissection and real-time rt-pcr in a study of hpv oncogene expression in cervical intraepithelial neoplasia and cancer
|
|
Add to my agenda | ||
| L |
P-267: DIFFERENTIATION DEPENDENT METHYLATION PATTERNS OF THE HPV16 GENOME WITHIN E6 AND E7 OPEN READING FRAMES.
|
|
Add to my agenda | ||
| L |
P-269: Differences in replication due to intra-type variations of HPV18.
|
|
Add to my agenda | ||
| L |
P-270: Efficient suppression of E6 and E7 gene expression and the growth of HPV16/HPV18-induced tumor in mouse model by REBACIN, a novel antiviral factor
|
|
Add to my agenda | ||
| L |
P-271: HIV protease inhibitors change the growth and differentiation of primary gingival keratinocytes and infectivity of HPV 16
|
|
Add to my agenda | ||
| L |
P-272: HPV E7 Induces G2-Arrest Following S-Phase Reentry in Differentiated Human Keratinocytes
|
|
Add to my agenda | ||
| L |
P-273: EFFECT OF HPV18 E2 VARIANT PROTEINS IN CELL DEATH SIGNALING PATHWAYS
|
|
Add to my agenda | ||
| L |
P-274: Stimulation of TNF-induced NFkB activation by the E2 protein of HPV
|
|
Add to my agenda | ||
| L |
P-275: SEROLOGY FOR MERKEL CELL POLYOMAVIRUS (MCV) USING PSEUDOVIRION-HEPARIN-LUMINEX CORRELATES WITH MCV DNA
|
|
Add to my agenda | ||
| L |
P-276: Mutations in HPV 16 L1 loops impair L2 binding
|
|
Add to my agenda | ||
| L |
P-277: The HPV-16 E5 protein represses XBP-1 and COX-2 stress signaling in genital keratinocytes.
|
|
Add to my agenda | ||
| L |
P-278: BIOLOGICAL EFECT OF HPV18 E6*I
|
|
Add to my agenda | ||
| L |
P-279: E6-AP as a potential therapeutic target for HPV-related diseases
|
|
Add to my agenda | ||
| L |
P-280: HPV E1 contains a region similar to the p53 transactivation domain required for DNA replication
|
|
Add to my agenda | ||
| L |
P-281: Nuclear Import of Low Risk HPV11 E7 Mediated by its Zinc Binding Domain is Independent of Nuclear Import Receptors
|
|
Add to my agenda | ||
| L |
P-282: The HPV-16 E5 Oncoprotein Inhibits EGF Receptor Trafficking Independently of Endosome Acidification
|
|
Add to my agenda | ||
| L |
P-283: Comparative study on E6 and E7 genes of 17 genital HPVs for their oncogenic activities
|
|
Add to my agenda | ||
| L |
P-284: HPV11 AND HPV16 infect human mammary epithelial cells
|
|
Add to my agenda | ||
| L |
P-285: Capsid determinants of HPV31 and HPV16 early infection events in human keratinocytes
|
|
Add to my agenda | ||
| L |
P-286: The contribution of epithelial wounding to HPV early infection events
|
|
Add to my agenda | ||
| L |
P-287: HIV-tat facilitates paracellular penetration of HPV into mucosal epithelium
|
|
Add to my agenda | ||
| L |
P-288: Temporal roles for native human papillomavirus type 16 conserved L1 cysteines in virion morphogenesis
|
|
Add to my agenda | ||
| L |
P-289: Differences in early entry events between high-risk native papillomaviruses
|
|
Add to my agenda | ||
| L |
P-290: Decreasing CDK1 Activity Induces The Synthesis of Non-Infectious Virions Exposed to Benzo[a]pyrene.
|
|
Add to my agenda | ||
| L |
P-291: Nucleosome positioning on episomal human papillomavirus DNA in cultured cells
|
|
Add to my agenda | ||
| L |
P-292: E1^E4 contributes to HPV life cycle completion but is not essential
|
|
Add to my agenda | ||
| L |
P-293: The role of hScrib stabilisation of E6 in the persistence of viral episomes
|
|
Add to my agenda | ||
